NextCure, Inc. (NASDAQ:NXTC) Receives $23.00 Average Price Target from Analysts

NextCure, Inc. (NASDAQ:NXTC) has been assigned a consensus rating of “Hold” from the five brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $23.00.

Several research analysts have issued reports on NXTC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a report on Monday, April 27th. Zacks Research cut shares of NextCure from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th.

NextCure Trading Up 4.6%

NASDAQ NXTC opened at $10.25 on Friday. The company’s 50-day moving average price is $11.03 and its 200-day moving average price is $11.67. The stock has a market cap of $37.00 million, a PE ratio of -0.60 and a beta of 1.43. NextCure has a 12 month low of $4.60 and a 12 month high of $15.74.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. As a group, sell-side analysts forecast that NextCure will post -7.91 earnings per share for the current year.

Institutional Trading of NextCure

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of NextCure in the 4th quarter valued at about $160,000. Millennium Management LLC purchased a new position in shares of NextCure in the 4th quarter valued at approximately $185,000. Geode Capital Management LLC raised its position in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of NextCure in the 4th quarter valued at approximately $988,000. 42.65% of the stock is currently owned by institutional investors.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.